FTC Launches ‘Colonoscopy’ Into PBM Practices, Including Focus On Consumer Costs, Access

Study will examine how the six largest pharmacy benefit managers in the US handle 10 disease categories. Federal Trade Commissioners unanimously support inquiry after its scope was broadened from an earlier version that drew objections from Republicans.

FTC magnifying glass
Study Description Demonstrates FTC Interest In 'Trying To Get To The Bottom' Of Complaints Against PBMs • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The Federal Trade Commission is moving ahead with a comprehensive study into potentially anti-competitive practices by US pharmacy benefit managers by sending them compulsory orders seeking detailed information on rebate-driven formulary practices, their dealings with pharmacies and how they interact with affiliates, among other topics. The decision could be welcomed by the pharmaceutical industry, which has long tried to convince policymakers that PBMs are significant contributors to high drug prices. 

More from Pricing Debate

More from Market Access

England’s NICE Wants Industry Involvement In HTA Sandbox Projects

 

Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.

PBMs Must Prepare For Revival Of Drug Price Transparency Requirements

 

Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.

Is Optum Rx Payment Remodel To Favor Generics A Peace Offering For US FTC?

 

Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.